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 2 
Abstract  28 
INTRODUCTION,  29 
Exploring the role of Alzheimer’s disease (AD) implicated pathways in pre-dementia phase may 30 
provide new insight for preventive and clinical trials targeting disease specific pathways.  31 
METHODS,   32 
We constructed weighted Genetic Risk Scores, first based on 20 genome-wide significant AD 33 
risk variants, second clustering these variants within pathways. Risk scores were investigated 34 
for their association with AD, mild cognitive impairment (MCI) and brain magnetic resonance 35 
imaging phenotypes including white matter lesions, hippocampal volume and brain volume.  36 
RESULTS,  37 
The risk score capturing endocytosis pathway was significantly associated with MCI (P = 38 
1.44x10-4). Immune response (P = 0.016) and clathrin/AP2 adaptor complex pathway (P = 39 
3.55x10-3) excluding apolipoprotein E (APOE) also showed modest association with white 40 
matter lesions but did not sustain Bonferroni correction (P = 9.09x10-4). 41 
DISCUSSION,   42 
Our study suggests that the clinical spectrum of early AD pathology is explained by different 43 
biological pathways in particular, the endocytosis, immune response and clathrin/AP2 adaptor 44 
complex pathways that are independent of APOE. 45 
Keywords: Genetic Risk Score, Alzheimer’s disease, White matter lesions, Mild cognitive 46 
impairment, Endocytosis, Immune response 47 
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Introduction  48 
Alzheimer’s disease (AD) is heterogeneous and genetically complex disease with a high 49 
heritability (56-79 %) [1].  It has been known since the end of the previous century that a 50 
polymorphism in the apolipoprotein E (APOE) gene is the strongest common genetic risk factor 51 
[2-4]. This finding fueled speculations on the role of lipid metabolism and cholesterol transport 52 
pathway in AD in addition to the amyloid cascade and tau phosphorylation mechanism [5, 6]. 53 
Furthermore, large-scale genome-wide association studies (GWAS) have discovered over 20 54 
novel common genetic variants that influence the risk of late-onset AD [7-13]. These common 55 
genetic variants have been mapped to eight biological pathways including  immune response, 56 
endocytosis, cholesterol transport, hematopoietic cell lineage, protein ubiquitination, 57 
hemostasis, clathrin/AP2 adaptor complex and protein folding, each having a distinct biological 58 
function [14-16]. These eight pathways are not independent in that genes may be part of more 59 
than one biological pathway. For instance, APOE is part of four of the eight pathways namely 60 
cholesterol transport, hematopoietic cell lineage, clathrin/AP2 adaptor complex and protein 61 
folding pathways; clusterin (CLU) encoding for apolipoprotein J is involved in six pathways; 62 
phosphatidylinositol binding clathrin assembly protein(PICALM) and complement factor 1 (CR1) 63 
are involved in 2 pathways [14-16].  64 
These diverse biological pathways may be responsible for the clinically heterogeneous 65 
manifestation of AD [17-19], which include endophenotypes such as changes in structural and 66 
functional magnetic resonance imaging (MRI) phenotypes, most notably hippocampal volume, 67 
total brain volume and white matter lesions [20, 21]. Furthermore, these biological pathways 68 
may also modulate the prodromal stages of AD such as mild cognitive impairment (MCI) [22-69 
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24]. Owing to heterogeneity during pre-dementia phase, one important unanswered question is 70 
whether the different biological pathways that are implicated in AD relate to the pleiotropy of 71 
clinical endophenotypes. We hypothesized that some biological pathways are involved in 72 
distinct clinical endophenotypes while others may be involved in multiple or even all. 73 
Disentangling the connection of biological pathways to various aspects of AD related early 74 
pathology may be a crucial step towards improving our understanding of the pathogenesis of 75 
AD and a first step towards a more informative and powerful read-out for preventive and 76 
therapeutic trials targeting specific pathways.  77 
The current study aims to capture the different biological pathways involved in AD using 78 
genetic risk scores to evaluate their role in AD and pre-dementia endophenotypes including 79 
MCI, white matter lesion, total brain and hippocampal volume.  80 
Methodology 81 
Study population 82 
This study included samples from the Rotterdam study (RS). RS is a prospective population 83 
based study [25] designed to investigate the etiology of age related disorders. At the baseline 84 
examination in 1990-93, study recruited 7983 subjects ≥ 55 years of age from the Ommoord 85 
district of Rotterdam (RS-I). At the baseline entry and after every 3 to 4 years, all the study 86 
participants were extensively interviewed and physically examined at the dedicated research 87 
center. During 2000 to 2001, the baseline cohort (RS-I) was expanded by adding 3011 subjects 88 
≥55 years of age, who were not yet part of RS-I (RS-II). Second expansion of RS was performed 89 
by recruiting 3932 persons having ≥45 years of age during 2006-2008 (RS-III). The study has 90 
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been approved by the Medical Ethical Committee of Erasmus Medical Center and by the 91 
Ministry of Health, Welfare and Sport of the Netherlands. Written Informed consents were also 92 
obtained from each study participant to participate and to collect information from their 93 
treating physicians. Details of AD, dementia and MCI diagnosis is provided elsewhere [26, 27]. 94 
In the current analyses, we included in total 1270 late-onset AD cases and 7623 controls (age at 95 
follow-up ≥ 65 years and dementia free) from RS-I (1118 cases, 4736 controls), RS-II (134 cases, 96 
1928 controls) and RS-III (18 cases, 959 controls) cohorts, from follow-up conducted during 97 
2009-2013. 10370 dementia free (Normal) participants were also included in study from all 98 
three RS baseline cohorts and followed for an average of 11 years to analyze their progression 99 
into incident AD. Further, we included 360 MCI cases and 3245 cognitively normal controls from 100 
RS-I (235 cases, 1943 controls) and RS-II (125 cases, 1302 controls) who were first time assessed 101 
during 2002-2005 in RS (Table 1).  102 
Genotyping 103 
Blood was drawn for genotyping from participants of RS cohort during their first visit and DNA 104 
genotyping was performed at the internal genotyping facility of Erasmus Medical Center, 105 
Rotterdam. All samples were genotyped with the 550K, 550K duo, or 610K Illumina arrays. 106 
Genotyping quality control criteria include, call rate < 95%, Hardy-Weinberg equilibrium P < 107 
1.0x10-6 and Minor Allele Frequency (MAF) < 1%. Moreover, study samples with excess 108 
autosomal heterozygosity, call rate < 97.5%, ethnic outliers and duplicate or family 109 
relationships were excluded during quality control analysis. Genetic variants were imputed 110 
from the Haplotype Reference Consortium (HRC) reference panel (version 1.0) [28], using the 111 
Michigan imputation server [29]. The server uses SHAPEIT2 (v2.r790) [30] to phase the 112 
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genotype data and performs imputation with Minimac 3 software [31]. For this study we used 113 
only genetic variants that had imputation quality (R-squared) > 0.5. 114 
MRI scanning  115 
Image acquisition  116 
MRI scanning is assessed on a 1.5-T MRI unit with a dedicated eight-channel head coil (Signa HD 117 
platform, GE Healthcare, Milwaukee, USA) since the induction of a dedicated MRI machine in 118 
the Rotterdam Study in 2005. The MRI protocol was based on several high-resolution axial 119 
sequences, including a T1-weighted (slice thickness 0.8 mm), T2-weighted (1.6 mm), and fluid 120 
attenuated inversion recovery sequence (2.5 mm). A detailed description of the MRI protocol is 121 
described previously [32]. 122 
Image processing 123 
we excluded 251 persons with stroke and/or dementia from the total 5899 subjects who 124 
came for MRI, since this may affect image processing. All T1 images were segmented into 125 
supratentorial gray matter, white matter and cerebrospinal fluid using a k-nearest neighbor 126 
(kNN) algorithm [33]. White matter lesions were segmented based on T1 tissue maps and 127 
an automatically detected threshold for the intensity of fluid-attenuated inversion recovery 128 
(FLAIR) scans [34]. After visual inspection of all segmentations, an additional 313 subjects 129 
were excluded due to poor quality, leaving 5335 for the analysis. The hippocampus was 130 
segmented using a fully automated method, described previously [35]. Semi-quantitative 131 
MRI post-processing software were used to measure intracranial volume and brain volume 132 
which included Elastix and custom-built software [36]. To calculate intracranial volume, 133 
non-brain tissues (skull, eyes, dura) were removed by non-linearly registering all brain 134 
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scans to a manually created template in which nonbrain tissues were masked. In all scans, 135 
visual checks were performed and if needed any segmentation errors manually corrected 136 
[36-38]. After excluding subjects whose genotyping information was not available, we 137 
ended up with 4527 cognitively normal subjects collectively from RS cohorts including RS-I 138 
(968), RS-II (1074) and RS-III (2485) cohorts for our current analyses. 139 
Statistical analysis  140 
Genetic Risk Score computation   141 
To construct the genetic risk score, we selected late-onset AD associated single nucleotide 142 
polymorphisms (SNPs) reaching genome-wide significance level (P < 5.0x10-8; Supplementary 143 
Table 1), including one rare TREM2 variant [7, 39]. In common variants, we considered only 144 
variants identified by the International Genomics of Alzheimer's Project (IGAP) meta-analyses. 145 
Additionally, we considered APOE*4 (rs429358) variant for genetic risk score construction. 146 
From a total of 21 SNPs, HLA-DRB1-HLA-DRB5 (rs9271192) variant was excluded from GRS 147 
calculation because of its low imputation quality (R-squared = 0.31) in RS. This led to a final 148 
selection of 20 independent genome-wide significant AD associated variants. Weighted genetic 149 
risk score was constructed using the effect sizes (log of OR) of the genome-wide significant 150 
variants from IGAP meta-analysis [7] as weights and their respective allele dosages from 151 
imputed genotype data of our study cohorts. Genetic risk score was constructed as the sum of 152 
the products of SNP dosages and their corresponding weights in R software (https://www.R-153 
project.org/). We constructed genetic risk score in two ways; 1) Combining all 20 selected 154 
variants and 2) Clustering the variants into their respective pathways. 155 
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1-Combined Genetic Risk Score (GRS1)  156 
GRS1 was constructed in two ways, i.e., 1) using all the 20 selected SNPs and 2) excluding the 157 
APOE*4 variant to identify the joint independent effect of all other genome-wide significant 158 
SNPs. 159 
2-Pathway-specific Genetic Risk Score (GRS2) 160 
For GRS2, the genome-wide significant AD SNPs were divided into pathways (immune response, 161 
endocytosis, cholesterol transport, hematopoietic cell lineage, protein ubiquitination, 162 
hemostasis, clathrin/AP2 adaptor complex and protein folding pathway) identified by Jones et 163 
al. 2014 [16] (Supplementary Table 2). Classifying genome-wide significant AD SNPs into 164 
pathways, we also utilized information from Guerreiro et al, 2013 [14], in which the authors 165 
reviewed the possible division of known AD associated genes into biological pathways [14]. 166 
Further, Gene Network database (http://129.125.135.180:8080/GeneNetwork/) was used to 167 
confirm the allocated pathways. Of the 20 SNPs 14 could be clustered into 7 non mutually 168 
exclusive pathways (Supplementary Table 2). Similar to GRS1, we also constructed GRS2 with 169 
and without the APOE*4 variant.  APOE*4 variant was grouped under four pathways including 170 
cholesterol transport [14], hematopoietic cell lineage, clathrin/AP2 adaptor complex and protein 171 
folding [16]. GRS2 was constructed for only those pathways, which could be assigned at least 172 
two SNPs, therefore protein ubiquitination pathway, which contained only one SNP, was 173 
excluded from all analyses, while hematopoietic cell lineage and protein folding pathways were 174 
also not considered in the analyses excluding APOE*4 variant.   175 
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Association analyses of GRS1, GRS2  176 
To test the association of AD and MCI with the risk scores we used logistic regression analysis in 177 
R software (www.R-project.org), using disease status as the outcome, risk scores as predictor 178 
and age and sex as covariates. In order to assess the possible inflation of association results 179 
between AD and risk scores, we repeated the association analysis excluding 625 AD cases which 180 
were part of IGAP meta-analysis [7] from total 1270 AD cases of the RS cohort. Further, we 181 
performed prospective analysis using Cox-proportional hazards model (N=1057 incident AD 182 
cases) in R software using ‘survival’ package [40] and reported results as hazard ratio (HR) per 1 183 
standard deviation (SD) increase in risk score and 95% confidence interval. The association of 184 
single variants with AD and MCI in a logistic regression model adjusted for age and sex. Results 185 
of association analyses were reported as unstandardized regression coefficient and P values.  186 
To test the association of MRI phenotypes including total brain volume, white matter lesions 187 
and hippocampal volume with the risk scores we used linear regression adjusted for age, sex 188 
and intracranial volume at MRI scan. Single variant association analysis was also performed for 189 
MRI phenotypes. Bonferroni correction (0.05/(11 risk scores x 5 phenotypes); P = 9.09x10-04 190 
was used to correct for multiple testing. 191 
Results  192 
Association of the GRS1 with AD, MCI and MRI endophenotypes  193 
The risk score containing all SNPs i.e., GRS1 both including APOE*4 (effect = 0.73, P = 6.53x10-74) 194 
and excluding APOE*4 (effect = 0.69, P = 1.12x10-11) was significantly associated with an 195 
increased risk of AD (Table 2). This association remained significant (APOE excluding; effect = 196 
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0.66, P = 8.47x10-7) after removing the patients that were included in the IGAP meta-analysis 197 
[7] (Supplementary Table 3). GRS1 was also significantly associated with progression of normal 198 
subjects into incident AD including (HR = 1.69, P = 6.64x10-83) and excluding APOE*4 (HR = 1.27, 199 
P = 4.88x10-15; Supplementary Table 4). GRS1 was associated with MCI when APOE*4 was 200 
included (effect = 0.19, P = 0.012) but the association was stronger with MCI when APOE*4 was 201 
excluded from the analysis (effect = 0.59, P = 9.51x10-4; Table 3), but these associations did not 202 
pass multiple testing correction. No association of GRS1 was observed with any of the MRI 203 
phenotypes: white matter lesions, hippocampal volume, and total brain volume (Table 4). 204 
Association of the GRS2 with AD  205 
Among GRS2 of which APOE*4 is a part, cholesterol transport, hematopoietic cell lineage, 206 
clathrin/AP2 adaptor complex and protein folding were significantly associated with AD (effect 207 
≥ 0.71, P < 3.22x10-64) only when APOE*4 was included in the risk scores (Table 2). Among the 208 
non-APOE pathways, AD was significantly associated with GRS2 capturing immune response 209 
(effect = 0.69, P = 3.20*10-5) and endocytosis pathway (effect = 0.75, P = 1.28x10-5) and 210 
association sustained (Immune response; effect = 0.68, P = 2.22x10-3 and endocytosis; effect = 211 
0.79, P = 5.37x10-4) after removing the patients that were included in the IGAP meta-analysis 212 
[7] (Supplementary Table 3). GRS2 capturing immune response (HR = 1.14, P = 1.19x10-5), 213 
endocytosis (HR = 1.19, P = 5.16x10-8) and APOE*4 excluded clathrin/AP2 adaptor complex (HR 214 
= 1.09, P = 5.98x10-3) pathway showed association with conversion risk from normal into 215 
incident AD. Both Immune response and endocytosis pathways were significant after multiple 216 
testing. GRS2 including APOE*4 were also significantly associated with normal to AD conversion 217 
(HR ≥ 1.60, P ≤ 1.44x10-69; Supplementary Table 4). Comparatively, except for APOE*4, CR1 and 218 
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BIN1, no single variant showed significant evidence of association (Supplementary Table 5). 219 
BIN1 as a part of endocytosis pathways also partially explains the association of GRS2 capturing 220 
endocytosis with AD. 221 
Association of the GRS2 with MCI  222 
In GRS2, only endocytosis pathway showed significant evidence for association (effect = 1.16, P 223 
= 1.44x10-4; Table 3) with MCI and it retained significance after multiple testing. Although the 224 
significance of the association is similar to that of the overall risk score (GRS1), the effect 225 
estimate is considerably higher (1.16 versus 0.59 overall). In the single variant analysis, the 226 
strongest association of MCI was observed with rs6733839 in the BIN1 gene (effect = 0.262, P = 227 
1.12x10-3; Supplementary Table5) but this association lost significance after Bonferroni 228 
correction. Whereas BIN1 is part of the endocytosis pathway, which partially explains the 229 
association between MCI and GRS2 capturing endocytosis.  230 
Association of the GRS2 with MRI phenotypes 231 
White matter lesions were associated with GRS2 capturing immune response (effect = 0.15, P = 232 
0.016), and clathrin/AP2 adaptor complex excluding APOE*4 (effect = 0.26, P = 3.55x10-3). If we 233 
consider multiple testing, both these associations loses significance after accounting for all 234 
tested phenotypes and risk scores. Of note is that the association of the GRS2 capturing the 235 
clathrin/AP2 adaptor complex loses its association when APOE*4 is included in the GRS2 (effect 236 
= 0.011, P = 0.507). We did not observe association of GRS2 with hippocampal volume and total 237 
brain volume. In the single variant analysis association of white matter lesions is seen with 238 
variants in PICALM, CLU genes (P ≤ 0.05). Hippocampal volume shows association with variants 239 
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in BIN1 and CELF1 genes (P < 0.05; Supplementary Table 6). None of the single variant 240 
association sustained Bonferroni correction.  241 
Discussion 242 
Combined GRS1 including and excluding APOE*4 is significantly associated with AD but not with 243 
MCI and MRI phenotypes in our study. Our study shows that the GRS2 capturing immune 244 
response and endocytosis pathways are not only significantly associated with AD, normal to AD 245 
conversion but also its endophenotypes, for instance, the GRS2 capturing the endocytosis 246 
pathway also associates significantly with MCI, a group at high risk of developing AD [41, 42], 247 
while the GRS2 capturing Immune response and clathrin/AP2 adaptor complex showed modest 248 
association with the presence of white matter lesions at MRI in cognitively normal subjects in 249 
the RS cohort (Supplementary Figure 1). 250 
In our study, the association of GRS1 with AD is consistent with other similar studies on AD [43-251 
45]. GRS1 association with MCI did not pass Bonferroni correction while other studies observed 252 
significant association of combined risk score with MCI [46, 47]. We did not find association of 253 
GRS1 with any of the studied MRI endophenotypes. These findings are consistent with those of 254 
Mormino et al. 2016 [48] and Lupton et al. 2016 [49], both studies did not find association of 255 
hippocampal volume with combined GRS1 based on genome-wide signficant AD variants but 256 
Mormino et al. 2016 [48] observed this association only with risk score based on non-genome 257 
wide significant AD variants. The largest study so far that included RS, however, reported 258 
significant evidence of association of risk score based on all genome-wide signficant AD variants 259 
with hippocampal volume and total brain volume [27].   260 
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This is the first study that addressed the role of specific pathways in AD and its early clinical 261 
manifestations i.e., MCI and MRI phenotypes. Our study shows that GRS2 based on immune 262 
response pathway was significantly associated with AD, normal to AD conversion. We also 263 
observed evidence of association of immune response with white matter lesions at MRI but this 264 
did not pass Bonferroni correction, therefore should be considered carefully while interpreting 265 
results. These findings are converging with studies showing enrichment of immune system 266 
pathway with non-genome wide significant AD variants [16, 50]. The genes clustered in immune 267 
response pathway (CLU, CRI, INPP5D, MS4A6A, TREM2, MEF2C, EPHA1) are mainly expressed in 268 
microglial cells and play a part in the innate immune response in central nervous system [51-269 
55]. Microglial cells are also thought to play a role in amyloid plaque clearance [56, 57]. It has 270 
been hypothesized that activation of immune system and the subsequent inflammatory 271 
response are involved in neuronal damage including axonal loss and white matter pathology 272 
due to demyelination [58]. This may explain the association of the AD genes involved in the 273 
immune response with white matter lesions that we observed in the present study [59]. Whit 274 
matter lesions are associated with increased risk of cognitive decline, developing dementia [21] 275 
and AD [60, 61]. White matter lesions are also more frequently observed in AD patients than 276 
controls [62, 63].  277 
The present study reveals further that the genes capturing the endocytosis pathway not only 278 
strongly associate to AD but also to MCI. We also showed that endocytosis pathway is also 279 
associated with progression from normal (dementia free) to AD in average 11 years of follow-280 
up. This pathway is independent of APOE and includes the BIN1, PICALM, CD2AP, SORL1 genes. 281 
We show that the association of GRS1 with MCI status is mainly attributed to the genes 282 
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involved in the endocytosis pathway. Omitting the AD genes not related to the endocytosis 283 
pathway makes the association of the pathway with MCI even stronger. The association 284 
suggests that the endocytosis pathway plays a critical role in an early prodromal phase of AD 285 
and converges with studies suggesting activation of endocytic pathway is the earliest reported 286 
intracellular manifestation of AD [41, 42, 64]. Based on the effect estimates of association of 287 
endocytosis pathway with AD and MCI (0.79 vs 1.59), we also speculated that endocytosis is 288 
more strongly associated to MCI than to AD. MCI is considered a prodromal stage in AD 289 
patients that suggest endocytosis pathway is associated with early pathology of AD. The 290 
endocytosis pathway is involved in neuronal uptake of macromolecules and secretory vesicles 291 
during synaptic transmission. As efficient uptake of extracellular cholesterol is critical for 292 
neuronal functions such as repair, synapse formation and exon elongation [65], normal 293 
neuronal work needs smooth functioning of endocytosis pathways [66]. Post-mortem studies 294 
have also demonstrated reduced brain cholesterol levels in the brain areas responsible for 295 
memory and learning, among late-onset AD cases and age matched controls [67]. These facts 296 
suggest that defects in endocytosis which derive the cholesterol uptake could lead to impaired 297 
neurotransmitter release and synaptic function [68]. Dysfunction in endocytosis can also 298 
contribute to accumulation of abnormal Aβ peptide [69]. Based on this finding, we can suggest 299 
that endocytosis pathway is a common molecular mechanism between MCI and AD that starts 300 
manifesting at early stages of disease. Risk contributed by variants clustered in this pathway at 301 
various stages of AD progression can possibly provide clue about disease trajectory. 302 
Similar to the immune response pathway, the clathrin/AP2 adaptor complex pathway modestly 303 
associated with white matter lesions. Although, the association failed to pass the multiple 304 
 15 
testing, but combined AD risk score did not capture the association with white matter lesions in 305 
our and even in large studies [27]. Capturing this association in small sample indicates the 306 
importance of this pathway in explaining the white matter lesions pathology. Two variants 307 
tagging PICALM and CLU genes cluster in the clathrin/AP2 adaptor complex pathway. Each 308 
variant independently shows nominally significant association with white matter lesions in our 309 
analyses but combining their effect are additive and improve the strength of association. There 310 
is a strong evidence that the two protein encoded by the genes interact at molecular level [70, 311 
71].  PICALM is involved in VAMP2 trafficking that is a crucial process to maintain functional 312 
integrity of synapses which are crucial to cognitive function [72, 73]. PICALM is also found to be 313 
expressed in the white matter and, immune-labeling of human brain tissue shows that PICALM 314 
is mainly found in blood vessel walls [74]. CLU clustered in clathrin/AP2 adaptor is involved in 315 
efflux of free insoluble amyloid beta (Aβ) peptide through blood brain barrier [75]. Increased 316 
plasma levels of CLU were found to be associated with increased burden of Aβ peptide in 317 
healthy elderly population and brain atrophy in AD [76, 77] and decreased integrity of white 318 
matter in young adults [78]. Demyelination of white matter is reported to occur even before 319 
the accumulation of Aβ plaques and neurofibrillary tangles [79]. The findings of the present 320 
study suggest that the increased genetic burden of risk variants in clathrin/AP2 adaptor 321 
complex (clathrin mediated endocytosis) and immune response pathway may play a role in early 322 
pathogenesis of AD through white matter pathology.   323 
Among pathways including APOE (Cholesterol transport, hematopoietic cell lineage, 324 
clathrin/AP2 adaptor complex, protein folding), significant association with AD and normal to 325 
AD conversion suggests that APOE*4 appear to be the driving genetic factor for these 326 
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associations. Only the clathrin/AP2 adaptor complex shows evidence of association (P = 0.036) 327 
to AD and normal to AD conversion (P = 5.98x10-3) when APOE*4 variant is excluded from the 328 
analysis but did not pass multiple testing correction.  329 
Our study provides a readout of pathway based risk score association with AD and its pre-330 
dementia endophenotypes. Main clinical significance of our findings is that they will allow to 331 
determine whether a certain biological pathway is involved in an individual patient. This will 332 
permit targeted interventions based on predicted pathological pathways. Similar as the case of 333 
cardiovascular diseases [80], a heterogeneous disease treatment can be followed based on 334 
pathway biomarkers (e.g., glucose level, total cholesterol and high density lipid levels, liver 335 
enzymes in case of cardiovascular disease) [81] but rather on genetic basis. This require 336 
reference pathways and treatment portfolio. In the meantime, the pathway based genetic risk 337 
score will allow stratification of the high risk patients in clinical trials based on causal pathways 338 
involved in patients. This may improve both the power and efficiency of future clinical and 339 
preventive trials. 340 
Our study is a step forward to use known genetic and pathway information for disentangling 341 
the mechanisms of AD but it has one major limitation that pathway information is based on 342 
known AD variants identified so far. This will further improve in future with improved genetic 343 
risk information that can better capture the underlying pathways. Another possible limitation of 344 
our study is that 625 cases of RS-I was a part of meta-analysis performed by IGAP [7] which can 345 
contribute to possible inflation in our results of association of risk score with AD. However, 346 
excluding these patients, the results of this study largely remained unchanged.  347 
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In conclusion we found different pathways are implicated in different endophenotypes of AD. 348 
Endocytosis pathway is involved in MCI and AD, while immune response associates with AD. 349 
Further, Immune response and clathrin/AP2 adaptor complex pathways are involved in white 350 
matter lesions but their association should be carefully considered due to multiple testing 351 
limitation. Interestingly, all the observed associations with early AD pathology are shown by 352 
APOE excluding pathways. Future findings from genomic research will improve the quality of 353 
the pathway-specific genetic scores. 354 
  355 
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Supplementary Figure 1: Diagram showing the association results of AD, MCI and WML in 590 cognitively normal subjects with pathways-specific GRS2 both including and excluding 591 
APOE*4. Bonferroni correction threshold (P = 9.09x10-4)  592 
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Supplementary Material  
Supplementary Table 1: List of Genome-wide significant variants associated with AD 
Chromosome Position (BP) SNP Gene Coding Allele Effect MAF RSI_Rsq RSII_Rsq RSIII_Rsq Effect origin 
1 207692049 rs6656401 CR1 G -0.157 0.197 0.953 0.948 0.950 Lambert et al. (2013)[1] 
2 127892810 rs6733839 BIN1 T 0.188 0.409 0.960 0.911 0.962 Lambert et al. (2013) 
2 234068476 rs35349669 INPP5D T 0.066 0.488 0.975 0.973 0.976 Lambert et al. (2013) 
5 88223420 rs190982 MEF2C A 0.08 0.408 0.979 0.934 0.978 Lambert et al. (2013) 
6 41129252 rs75932628 TREM2 T 0.889 0.0016 0.762 0.726 0.668 Ruiz et al. (2014)[2] 
6 32578530 rs9271192 HLA-DRB5-HLA-DRB1† A -0.108 0.276 0.314 0.312 0.314 Lambert et al. (2013) 
6 47487762 rs10948363 CD2AP G 0.098 0.266 0.998 0.998 0.998 Lambert et al. (2013) 
7 100004446 rs1476679 ZCWPW1 T 0.078 0.287 0.995 0.996 0.995 Lambert et al. (2013) 
7 143110762 rs11771145 EPHA1 A -0.102 0.338 0.998 0.998 0.999 Lambert et al. (2013) 
7 37841534 rs2718058 NME8 G -0.07 0.373 1.000 1.000 1.000 Lambert et al. (2013) 
8 27195121 rs28834970 PTK2B C 0.096 0.366 0.993 0.990 0.994 Lambert et al. (2013) 
8 27467686 rs9331896 CLU T 0.146 0.379 0.902 0.974 0.901 Lambert et al. (2013) 
11 121435587 rs11218343 SORL1 C -0.27 0.039 0.998 0.995 0.998 Lambert et al. (2013) 
11 47557871 rs10838725 CELF1 C 0.075 0.316 0.998 0.998 0.998 Lambert et al. (2013) 
11 59923508 rs983392 MS4A6A G -0.108 0.403 0.989 0.990 0.991 Lambert et al. (2013) 
11 85867875 rs10792832 PICALM G 0.13 0.358 0.999 0.999 0.999 Lambert et al. (2013) 
14 53400629 rs17125944 FERMT2 C 0.122 0.092 1.000 1.000 1.000 Lambert et al. (2013) 
14 92926952 rs10498633 SLC24A4-RIN3 T -0.104 0.217 0.999 0.999 1.000 Lambert et al. (2013) 
19 45411941 rs429358 APOE*4 C 1.3503 0.148 0.949 0.944 0.947 Lambert et al. (2013) 
19 1063443 rs4147929 ABCA7 G -0.135 0.19 0.916 0.917 0.991 Lambert et al. (2013) 
20 55018260 rs7274581 CASS4 C -0.139 0.083 0.990 0.989 0.990 Lambert et al. (2013) 
Abbreviations: AD ~ Alzheimer’s disease, MAF ~ minor allele frequency, Rsq = R-squared (HRC imputation quality) 
*Effect (log of odds ratio) is based on Coding Allele column   
† Variants have low imputation quality in HRC  imputation in our cohorts therefore excluded from genetic risk score calculation .  
 
 
Supplementary Table 2: Clustering of genome-wide significant variants into their respective 8 biological pathways. 
*SNPs classification into pathways is based on the information from Jones et al. [3] and Guerreiro et al[4].  
†APOE*4 variant (rs429358) is grouped under these pathways. Protein folding and Hematopoietic cell lineage pathways are left with one SNP 
after excluding APOE*4 variant therefore were not considered for APOE excluding analysis.  
 
   Genes reported in pathway Constructed GRS(Yes/No) 
Pathway Gene
* Assigned SNP Jones et al  Guerreiro et al Including 
APOE 
Excluding 
APOE 
Immune Response  
CLU rs9331896 Yes Yes 
No Yes 
CR1 rs6656401 Yes Yes 
INPP5D rs35349669 Yes Yes 
EPHA1 rs11771145 - Yes 
MS4A6A rs983392 - Yes 
TREM2 rs75932628 - Yes 
MEF2C rs190982 - Yes 
Endocytosis 
CD2AP rs10948363  Yes 
No Yes PICALM rs10792832 Yes Yes BIN1 rs6733839 Yes Yes 
SORL1 rs11218343 - Yes 
Cholesterol transport† 
CLU rs9331896 Yes Yes 
Yes Yes ABCA7 rs4147929 Yes Yes SORL1 rs11218343 - Yes 
 APOE*4 rs429358 Yes Yes 
Hematopoietic cell lineage† CR1 rs6656401 Yes - Yes No APOE*4 rs429358 Yes - 
Protein ubiquitination  CLU rs9331896 Yes - No No 
Hemostasis  CLU rs9331896 Yes - No Yes INPP5D rs35349669 Yes - 
Clathrin/AP2 adaptor complex† 
CLU rs9331896 Yes -   
PICALM rs10792832 Yes - Yes Yes 
APOE*4 rs429358 Yes -   
Protein folding† CLU rs9331896 Yes - Yes No APOE*4 rs429358 Yes  - 
Supplementary Table 3: Results of association of AD with risk scores 
  Including APOE Excluding APOE 
SNP Cluster* β SE P-value β SE P-value 
GRS1 (Combined ) 0.72 0.052 1.80x10-43 0.66 0.135 8.45x10-7 
Immune response - - - 0.68 0.221 2.22x10-3 
Endocytosis - - - 0.79 0.228 5.37x10-4 
Cholesterol Transport 0.70 0.054 3.48x10-38 0.41 0.294 0.159 
Hematopoietic cell lineage† 0.72 0.055 7.19x10-40  - - 
Hemostasis   - 0.35 0.390 0.364 
Clathrin/AP2 Adaptor complex 0.70 0.055 6.47x10-38 0.27 0.314 0.383 
Protein folding† 0.71 0.055 5.18x10-38  - - 
Abbreviations: GRS1 ~ Combined genetic risk score, SNP ~ single nucleotide polymorphism, β ~ regression coefficient, SE ~ Standard error.   
*Logistic regression model adjusted for age and sex in RS (N=645) excluding 625 cases included in IGAP meta-analysis   
†Only one SNP available in excluding APOE GRS2 
 
Supplementary Table 4: Results of longitudinal analysis from normal (dementia free) to AD conversion 
  Including APOE Excluding APOE 
SNP Cluster* HR 95% CI P-value HR 95% CI P-value 
GRS1 (Combined ) 1.69 1.61-1.79 6.64x10-83 1.27 1.19-1.34 4.88 x10-15 
Immune response - - - 1.14 1.07-1.21 1.19 x10-5 
Endocytosis - - - 1.19 1.12-1.26 5.16 x10-8 
Cholesterol Transport 1.60 1.52-1.68 1.44x10-69 1.07 1.01-1.14 2.45 x10-2 
Hematopoietic cell lineage† 1.60 1.52-1.68 4.29x10-71 - - - 
Hemostasis - - - 1.08 1.01-1.14 1.62 x10-2 
Clathrin/AP2 Adaptor complex 1.61 1.52-1.69 4.21x10-71 1.09 1.02-1.15 5.98 x10-3 
Protein folding† 1.60 1.52-1.68 7.66x10-70 - - - 
Note: Multiple testing correction by Bonferroni 0.05/ (5 phenotypes x 11 risk scores); P < 9.09x10-4  was considered significant 
Abbreviations: GRS1 ~ Combined genetic risk score, SNP ~ single nucleotide polymorphism,  
HR ~ Hazard ratio per 1 standard deviation of risk score, CI ~ Confidence interval 
*Cox proportional hazards model adjusted for age at baseline and sex in RS (N = 10370 normal at baseline) 
†Only one SNP available in excluding APOE GRS2 
 
 Supplementary Table 5: Results of single variant association with AD and MCI  
Phenotype  Alzheimer’s Disease Mild Cognitive Impairment 
SNP Gene β SE P-value β SE P-value 
rs429358 APOE*4 0.949 0.057 8.78x10-63 0.137 0.114 0.229 
rs75932628 TREM2 0.816 0.470 0.083 1.293 0.639 0.043 
rs6656401 CR1 -0.180 0.055 1.11x10-3 0.072 0.105 0.496 
rs11218343 SORL1 -0.161 0.110 0.142 -0.193 0.206 0.351 
rs10838725 CELF1 0.062 0.048 0.192 0.069 0.086 0.424 
rs983392 MS4A6A -0.081 0.045 0.072 -0.127 0.081 0.115 
rs10792832 PICALM 0.085 0.045 0.063 0.181 0.083 0.028 
rs17125944 FERMT2 0.128 0.070 0.067 -0.016 0.131 0.901 
rs10498633 SLC24A4-RIN3 -0.092 0.053 0.081 0.049 0.094 0.601 
rs4147929 ABCA7 -0.003 0.061 0.961 -0.064 0.107 0.552 
rs6733839 BIN1 0.149 0.045 9.74x10-4 0.262 0.081 1.12x10-3 
rs35349669 INPP5D 0.055 0.044 0.216 -0.081 0.080 0.315 
rs7274581 CASS4 -0.120 0.083 0.149 -0.034 0.143 0.810 
rs190982 MEF2C 0.010 0.046 0.833 0.061 0.083 0.458 
rs10948363 CD2AP 0.079 0.049 0.102 0.030 0.088 0.732 
rs1476679 ZCWPW1 0.005 0.047 0.918 -0.037 0.085 0.662 
rs11771145 EPHA1 -0.075 0.047 0.107 -0.117 0.085 0.168 
rs2718058 NME8 -0.051 0.045 0.258 0.054 0.081 0.507 
rs28834970 PTK2B 0.071 0.045 0.111 0.034 0.081 0.679 
rs9331896 CLU 0.049 0.047 0.290 0.026 0.084 0.762 
Note: Multiple testing correction by Bonferroni 0.05/ (5 phenotypes x 20 variants ); P < 5 x 10-4  was considered significant 
Abbreviations:  SNP ~ Single nucleotide polymorphism, β ~ regression coefficient, SE ~ Standard error 
 
 
 
  
Supplementary Table 6: Single variant association with MRI phenotypes  
 White matter lesions Hippocampal volume Total Brain volume 
SNP Gene β SE P-value β SE P-value β SE P-value 
rs429358 APOE*4       0.002 0.023 0.919 -0.001 0.023 0.973 0.004 0.010 0.676 
rs75932628 TREM2 0.276 0.221 0.212 -0.016 0.221 0.942 -0.050 0.093 0.591 
rs6656401 CR1 -0.003 0.022 0.893 -0.004 0.022 0.846 -0.012 0.009 0.187 
rs11218343 SORL1 -0.001 0.040 0.978 -0.045 0.040 0.265 -0.021 0.017 0.208 
rs10838725 CELF1 -0.005 0.018 0.765 0.036 0.018 0.041 0.008 0.007 0.275 
rs983392 MS4A6A -0.004 0.017 0.815 0.012 0.017 0.460 0.002 0.007 0.803 
rs10792832 PICALM 0.036 0.017 0.030 -0.007 0.017 0.667 -0.003 0.007 0.668 
rs17125944 FERMT2 0.009 0.027 0.723 -0.047 0.027 0.084 0.001 0.011 0.901 
rs10498633 SLC24A4-RIN3 -0.016 0.019 0.399 0.006 0.020 0.774 0.004 0.008 0.636 
rs4147929 ABCA7 0.023 0.022 0.285 0.010 0.022 0.664 0.006 0.009 0.488 
rs6733839 BIN1 0.008 0.017 0.621 -0.039 0.017 0.022 -0.002 0.007 0.814 
rs35349669 INPP5D 0.015 0.017 0.380 -0.016 0.017 0.328 -0.010 0.007 0.132 
rs7274581 CASS4 -0.012 0.030 0.676 -0.012 0.030 0.702 0.021 0.012 0.098 
rs190982 MEF2C 0.013 0.017 0.431 1.67x10-4 0.017 0.992 -0.011 0.007 0.127 
rs10948363 CD2AP -0.013 0.018 0.472 0.031 0.018 0.094 1.87x10-4 0.008 0.980 
rs1476679 ZCWPW1 -0.012 0.017 0.487 0.001 0.018 0.948 -0.005 0.007 0.513 
rs11771145 EPHA1 -0.024 0.017 0.157 -0.012 0.017 0.502 0.003 0.007 0.638 
rs2718058 NME8 0.009 0.017 0.608 -0.029 0.017 0.089 -0.001 0.007 0.912 
rs28834970 PTK2B -0.029 0.017 0.082 0.018 0.017 0.274 0.007 0.007 0.288 
rs9331896 CLU 0.034 0.017 0.051 -0.006 0.018 0.749 0.004 0.007 0.597 
Note: Multiple testing correction by Bonferroni 0.05/ (5 phenotypes x 20 variants ); P < 5 x10-4  was considered significant 
Abbreviations: MRI~ Magnetic resonance imaging, SNP ~ Single nucleotide polymorphism, β ~ regression coefficient, SE ~ Standard error 
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Table 1: Cohort characteristics  
Characteristics Rotterdam Study 
AD data set  
      Total  
      Late-onset AD 
      AD free controls 
       Age-of-onset (SD) 
      Females (%) 
 
8893 
1270 
84.30 (6.8) 
5228 (59%) 
MCI data set 
      Total  
      MCI cases 
      Controls  
      Age (SD) 
      Females (%) 
 
3605 
360 
71.9 (7.2) 
2063 (57%) 
MRI data set  
      Total 
       Age (SD) 
       Females (%) 
 
4527 
64.74 (10.8) 
2516 (56%) 
Abbreviation: SD ~ Standard deviation, AD ~ Alzheimer’s disease,  
MCI ~ Mild cognitive impairment, MRI ~ Magnetic resonance imaging 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Results of association of AD with risk scores GRS 
  Including APOE Excluding APOE 
SNP Cluster* β SE P-value β SE P-value 
GRS1 (Combined ) 0.73 0.040 6.53x10-74 0.69 0.101 1.12x10-11 
Immune response - - - 0.69 0.166 3.20x10-5 
Endocytosis - - - 0.75 0.171 1.28x10-5 
Cholesterol Transport 0.71 0.042 3.22x10-64 0.39 0.219 0.077 
Hematopoietic cell lineage† 0.73 0.042 5.16x10-66 - - - 
Hemostasis   - 0.50 0.292 0.090 
Clathrin/AP2 Adaptor complex 0.72 0.042 4.68x10-65 0.50 0.236 0.036 
Protein folding† 0.72 0.042 2.96x10-64 - - - 
Note: Multiple testing correction by Bonferroni 0.05/ (5 phenotypes x 11 risk scores); P < 9.09x10-4  was considered significant 
Abbreviations: GRS1 ~ Combined genetic risk score, SNP ~ Single nucleotide polymorphism, β ~ Regression coefficient, SE ~ Standard error.   
* Logistic regression model adjusted for age and sex in RS (N=1270 cases)  
†Only one SNP available in excluding APOE GRS2 
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Table 3: Results of association of MCI with risk scores GRS 
  Including APOE Excluding APOE 
SNP Cluster* β SE P-value β SE P-value 
GRS1 (combined) 0.19 0.075 0.012 0.59 0.179 9.51x10-4 
Immune response - - - 0.46 0.295 0.116 
Endocytosis - - - 1.16 0.305 1.44x10-4 
Cholesterol Transport 0.11 0.082 0.164 0.39 0.392 0.322 
Hematopoietic cell lineage† 0.09 0.084 0.269 - - - 
Hemostasis - - - -0.08 0.524 0.872 
Clathrin/AP2 Adaptor complex 0.12 0.082 0.128 0.72 0.423 0.089 
Protein folding† 0.10 0.083 0.218 - - - 
Note: Multiple testing correction by Bonferroni 0.05/ (5 phenotypes x 11 risk scores); P < 9.09x10-4  was considered significant 
Abbreviations: GRS1 ~ Combined genetic risk score, SNP ~ Single nucleotide polymorphism, β ~ Regression coefficient, SE ~ Standard error.   
* Logistic regression model adjusted for age and sex in RS (N=360 cases)  
† Only one SNP available in excluding APOE pathway based GRS2 
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Table 4: Results for association of risk scores GRS with MRI phenotypes 
 Including APOE Excluding APOE 
SNP cluster * White matter lesions Hippocampal volume Brain volume White matter lesions Hippocampal volume Brain volume 
 β SE P β SE P β SE P β SE P β SE P β SE P 
GRS1 (combined) 0.012 0.016 0.448 -0.001 0.016 0.929 0.002 0.007 0.806 0.059 0.037 0.114 -0.009 0.038 0.810 -0.006 0.016 0.724 
Immune response - - - - - - - - - 0.149 0.062 0.016 -0.024 0.062 0.706 -0.010 0.026 0.692 
Endocytosis - - - - - - - - - 0.071 0.062 0.254 -0.046 0.063 0.462 0.004 0.026 0.865 
Cholesterol Transport 0.005 0.017 0.785 0.001 0.017 0.964 0.004 0.007 0.574 0.063 0.080 0.434 0.013 0.080 0.875 0.023 0.033 0.497 
Hematopoietic cell lineage† 0.002 0.017 0.901 0.001 0.017 0.976 0.004 0.007 0.556 - - - - - - - - - 
Hemostasis  - - - - - - - - - 0.228 0.108 0.034 -0.077 0.109 0.479 -0.009 0.045 0.835 
Clathrin/AP2 Adaptor complex 0.011 0.017 0.507 -0.002 0.017 0.924 0.003 0.007 0.658 0.258 0.088 3.55x10-3 -0.077 0.109 0.479 -0.009 0.045 0.835 
Protein folding† 0.007 0.017 0.700 -0.001 0.017 0.970 0.004 0.007 0.619 - - - - - - - - - 
Note: Multiple testing correction by Bonferroni 0.05/ (5 phenotypes x 11 risk scores); P < 9.09x10-4  was considered significant 
Abbreviations: GRS1 ~ Combined genetic risk score, MRI ~ Magnetic resonance imaging, SNP ~ Single nucleotide polymorphism, β ~ Regression coefficient, SE ~ Standard error, P ~ P-value 
* Linear regression model with MRI phenotype as outcome and risk score GRS as predictor, adjusted for age at MRI scan, sex in RS (N=4527)  
† Only one SNP available in excluding APOE pathway based GRS2 
 
 
 
 
 
 
 
 
 
Formatted: Highlight
Formatted: Font: 8 pt
Formatted: Highlight
Formatted: Highlight
